35,533 Shares in Quanterix Co. (NASDAQ:QTRX) Purchased by Semanteon Capital Management LP

Semanteon Capital Management LP bought a new stake in Quanterix Co. (NASDAQ:QTRX) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 35,533 shares of the company’s stock, valued at approximately $971,000.

Several other large investors have also recently bought and sold shares of QTRX. Vanguard Group Inc. raised its position in Quanterix by 1.4% in the third quarter. Vanguard Group Inc. now owns 1,997,295 shares of the company’s stock worth $54,207,000 after acquiring an additional 26,660 shares in the last quarter. Invesco Ltd. lifted its stake in Quanterix by 49.6% during the third quarter. Invesco Ltd. now owns 1,103,981 shares of the company’s stock valued at $29,962,000 after purchasing an additional 366,117 shares during the last quarter. Lord Abbett & CO. LLC bought a new stake in Quanterix during the third quarter worth approximately $27,744,000. Boone Capital Management LLC grew its position in Quanterix by 13.4% in the third quarter. Boone Capital Management LLC now owns 568,544 shares of the company’s stock worth $15,430,000 after buying an additional 67,400 shares during the last quarter. Finally, Emerald Advisers LLC bought a new position in shares of Quanterix in the third quarter valued at $10,462,000. Institutional investors and hedge funds own 86.48% of the company’s stock.

Quanterix Trading Down 2.8 %

NASDAQ:QTRX traded down $0.45 during trading hours on Thursday, hitting $15.59. 290,993 shares of the stock traded hands, compared to its average volume of 347,367. Quanterix Co. has a fifty-two week low of $11.39 and a fifty-two week high of $29.70. The firm has a market cap of $596.32 million, a price-to-earnings ratio of -18.13 and a beta of 1.30. The firm has a 50 day moving average price of $23.16 and a 200 day moving average price of $23.46.

Quanterix (NASDAQ:QTRX) last issued its quarterly earnings data on Thursday, February 29th. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.05). Quanterix had a negative net margin of 26.42% and a negative return on equity of 9.15%. The business had revenue of $31.55 million for the quarter, compared to the consensus estimate of $27.92 million. Research analysts predict that Quanterix Co. will post -1.04 EPS for the current year.

Insider Activity at Quanterix

In other news, Director Laurie J. Olson sold 1,500 shares of Quanterix stock in a transaction dated Wednesday, February 14th. The stock was sold at an average price of $24.35, for a total value of $36,525.00. Following the transaction, the director now directly owns 15,238 shares in the company, valued at $371,045.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 6.80% of the stock is owned by company insiders.

Analyst Ratings Changes

Separately, Scotiabank raised their price objective on Quanterix from $30.00 to $32.00 and gave the stock a “sector outperform” rating in a research note on Monday, March 4th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $32.00.

Quanterix Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.